About this trial
Facial scars are frequently deemed unpleasant and can profoundly impact a patient's psychological health. This study compares the effectiveness, safety, and capacity to speed up scar healing in the maxillofacial region between fractional carbon dioxide (CO₂) laser therapy alone and polydeoxyribonucleotide (PDRN) combined with CO₂ laser therapy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age Limitations: Participants must be between 18 and 50 years of age.
Recently cut wounds or surgical scars from about (1-6 months).
Consent to Participate: Willingness to provide informed consent and engage in all aspects of the study.
Disqualifiers
Pregnancy or breastfeeding at the time of study.
Known allergy to PDRN.
Isotretinoin.
Anticancer drugs.
Trial design
Parallel
Treatments tested in this trial
Polydeoxyribonucleotide
Drugintralesional PDRN injections
Fractional CO2 laser assisted PDT
DeviceFractional carbon dioxide (CO₂) laser therapy for facial scars
Treatment groups
Trial outcomes
Primary outcomes
Vancouver Scar Scale
The study used the standard Vancouver Scar Scale, which evaluates four characteristics of scars: Total Score Range: 0 (normal skin) to 13 (severe hypertrophic scar)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.